MyMedR

Displaying all 4 publications

Abstract:

Sort:

Fulltext Interaction between Pasteurella multocida B:2 and its derivatives with bovine aortic endothelial cell (BAEC)

Kamal NM, Zamri-Saad M, Masarudin MJ, Othman S

BMC Vet Res, 2017 Jun 19;13(1):186.
PMID: 28629460 DOI: 10.1186/s12917-017-1109-1

BACKGROUND: Pasteurella multocida B:2 causes bovine haemorrhagic septicaemia (HS), leading to rapid fatalities in cattle and buffaloes. An attenuated derivative of P. multocida B:2 GDH7, was previously constructed through mutation of the gdhA gene and proved to be an effective live attenuated vaccine for HS. Currently, only two potential live attenuated vaccine candidates for HS are being reported; P. multocida B:2 GDH7 and P. multocida B:2 JRMT12. This study primarily aims to investigate the potential of P. multocida B:2 GDH7 strain as a delivery vehicle for DNA vaccine for future multivalent applications.
RESULTS: An investigation on the adherence, invasion and intracellular survival of bacterial strains within the bovine aortic endothelial cell line (BAEC) were carried out. The potential vaccine strain, P. multocida B:2 GDH7, was significantly better (p ≤ 0.05) at adhering to and invading BAEC compared to its parent strain and to P. multocida B:2 JRMT12 and survived intracellularly 7 h post treatment, with a steady decline over time. A dual reporter plasmid, pSRGM, which enabled tracking of bacterial movement from the extracellular environment into the intracellular compartment of the mammalian cells, was subsequently transformed into P. multocida B:2 GDH7. Intracellular trafficking of the vaccine strain, P. multocida B:2 GDH7 was subsequently visualized by tracking the reporter proteins via confocal laser scanning microscopy (CLSM).
CONCLUSIONS: The ability of P. multocida B:2 GDH7 to model bactofection represents a possibility for this vaccine strain to be used as a delivery vehicle for DNA vaccine for future multivalent protection in cattle and buffaloes.
Geochemical and mineralogical assessment of sedimentary limestone mine waste and potential for mineral carbonation

Mohd Isha NS, Mohd Kusin F, Ahmad Kamal NM, Syed Hasan SNM, Molahid VLM

Environ Geochem Health, 2021 May;43(5):2065-2080.
PMID: 33392897 DOI: 10.1007/s10653-020-00784-z

This paper attempts to evaluate the mineralogical and chemical composition of sedimentary limestone mine waste alongside its mineral carbonation potential. The limestone mine wastes were recovered as the waste materials after mining and crushing processes and were analyzed for mineral, major and trace metal elements. The major mineral composition discovered was calcite (CaCO3) and dolomite [CaMg(CO3)2], alongside other minerals such as bustamite [(Ca,Mn)SiO3] and akermanite (Ca2MgSi2O7). Calcium oxide constituted the greatest composition of major oxide components of between 72 and 82%. The presence of CaO facilitated the transformation of carbon dioxide into carbonate form, suggesting potential mineral carbonation of the mine waste material. Geochemical assessment indicated that mean metal(loid) concentrations were found in the order of Al > Fe > Sr > Pb > Mn > Zn > As > Cd > Cu > Ni > Cr > Co in which Cd, Pb and As exceeded some regulatory guideline values. Ecological risk assessment demonstrated that the mine wastes were majorly influenced by Cd as being classified having moderate risk. Geochemical indices depicted that Cd was moderately accumulated and highly enriched in some of the mine waste deposited areas. In conclusion, the limestone mine waste material has the potential for sequestering CO2; however, the presence of some trace metals could be another important aspect that needs to be considered. Therefore, it has been shown that limestone mine waste can be regarded as a valuable feedstock for mineral carbonation process. Despite this, the presence of metal(loid) elements should be of another concern to minimize potential ecological implication due to recovery of this waste material.
Fulltext The Asia Pacific Pediatric Association (APPA) position statement on the MAFLD definition of fatty liver disease

Memon IA, Parkash A, Sadiq K, Kamal NM, El-Shabrawi MHF

Ther Adv Chronic Dis, 2023;14:20406223231164523.
PMID: 37051073 DOI: 10.1177/20406223231164523
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease

Zhang L, El-Shabrawi M, Baur LA, Byrne CD, Targher G, Kehar M, et al.

Med, 2024 Jul 12;5(7):797-815.e2.
PMID: 38677287 DOI: 10.1016/j.medj.2024.03.017

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dyslipidemia. Experts have proposed an alternative terminology, metabolic dysfunction-associated fatty liver disease (MAFLD), to better reflect its pathophysiology. This study aimed to develop consensus statements and recommendations for pediatric MAFLD through collaboration among international experts.
METHODS: A group of 65 experts from 35 countries and six continents, including pediatricians, hepatologists, and endocrinologists, participated in a consensus development process. The process encompassed various aspects of pediatric MAFLD, including epidemiology, mechanisms, screening, and management.
FINDINGS: In round 1, we received 65 surveys from 35 countries and analyzed these results, which informed us that 73.3% of respondents agreed with 20 draft statements while 23.8% agreed somewhat. The mean percentage of agreement or somewhat agreement increased to 80.85% and 15.75%, respectively, in round 2. The final statements covered a wide range of topics related to epidemiology, pathophysiology, and strategies for screening and managing pediatric MAFLD.
CONCLUSIONS: The consensus statements and recommendations developed by an international expert panel serve to optimize clinical outcomes and improve the quality of life for children and adolescents with MAFLD. These findings emphasize the need for standardized approaches in diagnosing and treating pediatric MAFLD.
FUNDING: This work was funded by the National Natural Science Foundation of China (82070588, 82370577), the National Key R&D Program of China (2023YFA1800801), National High Level Hospital Clinical Research Funding (2022-PUMCH-C-014), the Wuxi Taihu Talent Plan (DJTD202106), and the Medical Key Discipline Program of Wuxi Health Commission (ZDXK2021007).